|
|
|
19 May 2008 |
First pre-pandemic vaccine approved to help protect against pandemic influenza
|
|
19 May 2008 |
Amikacin Inhale shows promising results in Phase II Study
|
|
19 May 2008 |
Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
|
|
16 May 2008 |
Arpida announces FDA acceptance of the Iclaprim new drug application
|
|
15 May 2008 |
Medivir AB broadens its Hepatitis C collaboration with Tibotec, entering a partnership in the fiels of HCV Polymerase
|
|
15 May 2008 |
Novavax completes enrollment in phase 1/IIa pandemic influenza vaccine clinical trial
|
|
14 May 2008 |
In a Phase II study, Novartis Meningitis B vaccine has potential to produce a protective immune response in infants[1], the age group most at risk
|
|
14 May 2008 |
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
|
|
13 May 2008 |
Start of Phase II Clinical Study for Rabies Monoclonal Antibody Combination in the Philippines
|
|
13 May 2008 |
AVI BioPharma Announces Significant Advance in the Potential Treatment of Ebola and Marburg Virus Infections
|
|
12 May 2008 |
Ranbaxy & Merck Sign Anti-infective Drug Discovery And Development Agreement
|
|
12 May 2008 |
Virostatics Doses First Patient in Phase IIa Trial of VS411 for the Treatment of HIV Infection
|
|
12 May 2008 |
Argos Therapeutics Initiates Phase 2 Proof-of-Concept Trial for its Arcelis(TM) Personalized Immunotherapy Platform in HIV
|
|
12 May 2008 |
NovaBay's Lead Aganocide Compound, NVC-422, Well Tolerated in the Bladder in Phase I Trial
|
|
09 May 2008 |
PolyMedix Receives Regulatory Clearance to Initiate Phase I Clinical Study of Novel Systemic Antibiotic Compound
|
|
07 May 2008 |
Regulatory Filing for FACTIVE Tablets Submitted in Europe
|
|
07 May 2008 |
iCo Therapeutics Acquires Worldwide Rights to iCo-009 (Oral Amphotericin B)
|
|
07 May 2008 |
Mycamine(R) Has Now Been Approved in Europe
|
|
06 May 2008 |
Novartis Menveo(R) vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial
|
|
06 May 2008 |
Omigard(TM) Phase III Pivotal Registration Study Enrollment Completed
|
|
02 May 2008 |
Protez initiates phase II study for its leaad product PZ-601 in infectious diseases
|
|
02 May 2008 |
Gilead Initiates Letairis(R) (ambrisentan) Phase IV Program
|
|
30 Apr 2008 |
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
|
|
29 Apr 2008 |
Inhibitex Initiates Phase I Trial of FV-100 for the Treatment of Shingles
|
|
29 Apr 2008 |
DOR BioPharma Initiates Non-Human Primate Efficacy Studies of RiVaxTM, Its Vaccine Against Ricin Toxin
|
|
28 Apr 2008 |
Clinical Update – Debio 025 in Hepatitis C - Presentation of Phase IIa Efficacy Results
|
|
28 Apr 2008 |
European Commission grants full approval of HIV protease inhibitor, tipranavir (Aptivus(R))
|
|
28 Apr 2008 |
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
|
|
26 Apr 2008 |
Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
|
|
26 Apr 2008 |
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
|
|
26 Apr 2008 |
Roche's Investigational Hepatitis C Polymerase Inhibitor, R1626, Demonstrated Significant End-of-Treatment Response in Phase IIa Study
|
|
25 Apr 2008 |
Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon and Ribavirin Treatment
|
|
25 Apr 2008 |
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
|
|
25 Apr 2008 |
Flamel Technologies Presents Results of Two Week Study of Interferon Alpha XL at the European Association for the Study of the Liver
|
|
25 Apr 2008 |
European Commission Approves Viread(R) for Chronic Hepatitis B
|
|
25 Apr 2008 |
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
|
|
24 Apr 2008 |
Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread(R) for the Treatment of Chronic Hepatitis B
|
|
24 Apr 2008 |
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb Data Presentation at European Association for the Study of Liver Annual Meeting
|
|
24 Apr 2008 |
More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
|
|
24 Apr 2008 |
Biolex Therapeutics Researchers Present Locteron® Phase 2a Hepatitis C Trial Results at EASL Conference
|
|
24 Apr 2008 |
First data on TMC435350 in patients with hepatitis C who have faild previous treatment shows antiviral activity
|
|
23 Apr 2008 |
Replidyne Discontinues Phase III Trial
|
|
23 Apr 2008 |
Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
|
|
22 Apr 2008 |
Single, Intramuscular (IM) Dose, Protects up to 75 Percent in Primate Study
|
|
21 Apr 2008 |
Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
|
|
18 Apr 2008 |
Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
|
|
18 Apr 2008 |
Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
|
|
17 Apr 2008 |
Arpida provides comprehensive overview of pivotal phase III trial data
|
|
17 Apr 2008 |
Alphavax announces initial analysis of data from CMV phase I clinical trial
|
|
17 Apr 2008 |
Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV(TM)
|
| |
|
Results 201 - 250 of 1267 |
